Ann: Kazia Annual Report to shareholders, page-3

".......Kazia’s paxalisib is about to enter the final step in this process, phase III human trials, and statistically this implies
approximately a 50% likelihood of it succeeding. However, the fact that the PI3K mechanism is very well-validated, and
the fact that paxalisib is targeting an orphan indication, both considerably enhance its chances of success. On balance,
paxalisib is considerably more likely at this stage to reach market than not......"